

March 24, 2021

Listing Department

Code: 532 321

BSE LIMITED

P J Towers, Dalal Street, Fort,

Mumbai – 400 001

Listing Department

Code: CADILAHC

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex,

Bandra (E),

Mumbai – 400 051

Re.: Press Release

Dear Sir/Madam,

Please find enclosed a copy of press release dated March 24, 2021 titled “Remdac™ (Remdesivir) from Zydus now more affordable at Rs.899”.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**

DHAVAL  Digitally signed by
DHAVAL
NARENDRA NARENDRA SONI
Date: 2021.03.24
SONI 13:57:48 +05'30'

DHAVAL N. SONI

COMPANY SECRETARY

Encl.: As above

Remdac™ (Remdesivir) from Zydus™ now more affordable at Rs. 899

Remdac™ (Remdesivir) India's most economical Remdesivir brand now made more affordable for patients.

Ahmedabad, India, March 24, 2021

In a significant move Zydus has made its brand of Remdesivir, Remdac™ more affordable at Rs. 899 for a 100 mg lyophilized injection. Remdac™ which was launched in August 2020 at Rs. 2800, continues to be India's most economical brand of Remdesivir and a critical drug in the treatment of COVID-19. This move to further revise the prices will go a long way in helping patients during these critical times.

Speaking on the development Dr. Sharvil Patel, Managing Director, Cadila Healthcare Limited said, "Through the course of this pandemic, our efforts have been focused on making therapies accessible and affordable to people. Remdac™ has been one of the critical drugs in the disease management on COVID and we hope that this price cut will enable people from every strata of the society to access this critical drug."

In June 2020, Zydus entered into a non-exclusive agreement with Gilead Sciences Inc., to manufacture and sell Remdesivir, the investigational drug, which has been issued an Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) to treat patients suffering from severe symptoms of COVID 19. The API for the drug has been developed and manufactured at the group's API manufacturing facilities in Gujarat.

For further information please contact :
The Corporate Communications Department

Cadila Healthcare Limited
Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, India.
Phone : +91-079-71800000, +91-079-48040000 www.zyduscadila.com
CIN : L24230GJ1995PLC025878